Seoul, South Korea

Sohyun Joo

This inventor holds 1 USPTO granted patent and 1 published patent application and 2 EPO patents. Top assignee: Neuroventi. Active years: 2025.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Sohyun Joo: Innovator in Developmental Disorder Treatments

Introduction

Sohyun Joo is a prominent inventor based in Seoul, South Korea. She has made significant contributions to the field of medical research, particularly in the treatment of developmental disorders. Her innovative work focuses on utilizing specific compounds to address complex health issues.

Latest Patents

Sohyun Joo holds a patent for a composition comprising a rilmenidine compound as an active ingredient for the treatment of fragile X syndrome and related developmental disabilities. The patent describes a composition aimed at preventing, improving, or treating fragile X syndrome, fragile X syndrome-related developmental disorders, autism spectrum disorder, or schizophrenia. This composition includes rilmenidine, a rilmenidine metabolite, or a pharmaceutically acceptable salt thereof. She has 1 patent to her name.

Career Highlights

Sohyun Joo is currently associated with Neuroventi, a company dedicated to advancing medical treatments. Her work at Neuroventi has positioned her as a key player in the research and development of therapies for developmental disorders.

Collaborations

Sohyun collaborates with talented individuals in her field, including Chanyoung Shin and Sejin Jeon. These partnerships enhance her research efforts and contribute to the advancement of innovative treatments.

Conclusion

Sohyun Joo's contributions to the field of developmental disorder treatments highlight her dedication to improving patient outcomes. Her innovative patent work and collaborations reflect her commitment to advancing medical science.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…